Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NTA-476 vs 18F-DCFPyL PET/CT in Prostate Cancer
NCT06520449Phase 1Completed
- Sponsor
- Melbourne Theranostic Innovation Centre
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-NTA-476 in prostate cancer (PCa), sponsored by Melbourne Theranostic Innovation Centre. Primary endpoints: Tumour uptake of 68Ga-NTA-476 compared to 18F-DCFPyL and Uptake and washout of 68Ga-NTA-476 in normal organs. Started Sep 2024; status: completed.
02
Drugs
68Ga-NTA-476
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06520449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06520449.